Sarepta Therapeutics Inc (NASDAQ:SRPT) shares shot up nearly 13% today in the wake of Dr. Ronald Farkas, arguably the most oppositional team leader …
Analyst Michelle Gilson of Oppenheimer feels confident about eteplirsen, a pipeline drug for Sarepta Therapeutics Inc (NASDAQ:SRPT), even though Santhera, a competitor of …